Edoxaban vs Dabigatran
## Overview
Edoxaban (Xa inhibitor) and dabigatran (thrombin inhibitor) represent different DOAC mechanisms. Both are once-daily options only in part of their dose ranges, with dabigatran twice daily. Key difference: dabigatran's high renal clearance vs. edoxaban's moderate.
## Mechanism of Action
Edoxaban: direct Xa inhibitor. Dabigatran: direct thrombin inhibitor (prodrug).
## Pharmacokinetics
Edoxaban: ~50% renal clearance, once daily, bioavailability ~62%, CrCl >95 restriction. Dabigatran: ~80% renal clearance, twice daily, bioavailability ~7%.
## Safety and Efficacy
ENGAGE AF-TIMI 48 (edoxaban): non-inferior to warfarin in AF with less major bleeding. RE-LY (dabigatran 150 mg): superior to warfarin for stroke prevention, with more GI bleeding and dyspepsia. Edoxaban has lower GI bleeding rates than dabigatran.
## Key Takeaways
- Edoxaban: once-daily advantage, lower GI effects than dabigatran
- Dabigatran: idarucizumab reversal; highest renal dependence
- Both have CrCl-based restrictions (different thresholds)
บทสรุป
Edoxaban is preferred over dabigatran for patients with moderate CKD or GI sensitivity. Dabigatran's specific reversal agent (idarucizumab) remains a unique advantage. For most patients, apixaban is preferred over both based on overall evidence profile.